We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug
Read MoreHide Full Article
Shares of Zymeworks (ZYME - Free Report) were up 23.6% on Dec 21 after management announced that partner Jazz Pharmaceuticals (JAZZ - Free Report) exercised an option under the recently entered collaboration agreement for licensing rights to the former’s lead candidate, zanidatamab.
Following the exercise of this option, Jazz will now hold exclusivedevelopment and commercialization rights to zanidatamab, Zymeworks' lead candidate, across all its indications in all territories except in Asia/Pacific territories where the drug has already been licensed to BeiGene (BGNE - Free Report) .
Earlier this October, Zymeworks and Jazz entered into an exclusive licensing agreement to develop and market zanidatamab. Following the signing of this agreement, Jazz made an upfront payment of $50 million to Zymeworks. As part of this agreement, Jazz was granted this exclusive option if it wished to continue with the collaboration further.
In consideration for exercising the option, Jazz will pay an upfront payment of $325 million to Zymeworks. This payment will be made by Merck in fourth-quarter 2022.
Shares of Zymeworks have lost 46.6% in the year compared to the industry’s 20.5% decline.
Image Source: Zacks Investment Research
Jazz’s decision to exercise its option is based on Zymeworks’ recently announced positive topline data from the pivotal phase IIb HERIZON-BTC-01 study, which evaluated zanidatamabin previously treated HER2-amplified biliary tract cancers (BTC). Data from the study showed that about 41% of study participants achieved an objective response. The median duration of response was 12.9 months. Based on this data, Jazz expects zanidatamab to become the next standard-of-care treatment in BTC.
Apart from the above payments, Zymeworks will also be eligible to receive regulatory milestone payments of up to $525 million and up to $862.5 million on the achievement of certain commercial milestones. Jazz will also be paying Zymeworks tiered royalties between 10% to 20% of the net sales if and when zanidatamab is approved and marketed. Thus, the deal has the potential to reach a total valuation of $1.76 billion.
Developed by Zymeworks, Zanidatamab is an investigational antibody candidate, which has been designed as a treatment option for patients with solid tumors that express HER2. The candidate is being evaluated by ZYME in multiple clinical studies targeting multiple oncology indications.
Apart from zanidatamab, Zymeworks is also developing zanidatamab zovodotin (ZW49) for a range of HER-2 expressing cancers. The candidate is currently undergoing a phase I study to establish its safety and antitumor activity in humans.
Zymeworks entered into a strategic collaboration with BeiGene in 2018, where the latter acquired the exclusive rights to develop and commercialize zanidatamab and zanidatamab zovodotin (ZW49) in Asia (excluding Japan), Australia and New Zealand. In return, ZYME received $40 million as an upfront payment from BeiGene. In addition, Zymeworks will also be entitled to receive development and commercial milestone payments of up to $390 million from BeiGene and potential royalties on future product sales.
Zymeworks currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Kamada , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Kamada’s 2022 loss per share have narrowed from 14 cents to 7 cents. During the same period, the earnings estimates per share for 2023 have risen from 26 cents to 42 cents. Shares of Kamada have declined 38.2% in the year-to-date period.
Earnings of Kamada beat estimates in two of the last four quarters and missed the mark twice, witnessing a negative earnings surprise of 62.50%, on average. In the last reported quarter, Kamada’s earnings beat estimates by 433.33%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug
Shares of Zymeworks (ZYME - Free Report) were up 23.6% on Dec 21 after management announced that partner Jazz Pharmaceuticals (JAZZ - Free Report) exercised an option under the recently entered collaboration agreement for licensing rights to the former’s lead candidate, zanidatamab.
Following the exercise of this option, Jazz will now hold exclusivedevelopment and commercialization rights to zanidatamab, Zymeworks' lead candidate, across all its indications in all territories except in Asia/Pacific territories where the drug has already been licensed to BeiGene (BGNE - Free Report) .
Earlier this October, Zymeworks and Jazz entered into an exclusive licensing agreement to develop and market zanidatamab. Following the signing of this agreement, Jazz made an upfront payment of $50 million to Zymeworks. As part of this agreement, Jazz was granted this exclusive option if it wished to continue with the collaboration further.
In consideration for exercising the option, Jazz will pay an upfront payment of $325 million to Zymeworks. This payment will be made by Merck in fourth-quarter 2022.
Shares of Zymeworks have lost 46.6% in the year compared to the industry’s 20.5% decline.
Image Source: Zacks Investment Research
Jazz’s decision to exercise its option is based on Zymeworks’ recently announced positive topline data from the pivotal phase IIb HERIZON-BTC-01 study, which evaluated zanidatamabin previously treated HER2-amplified biliary tract cancers (BTC). Data from the study showed that about 41% of study participants achieved an objective response. The median duration of response was 12.9 months. Based on this data, Jazz expects zanidatamab to become the next standard-of-care treatment in BTC.
Apart from the above payments, Zymeworks will also be eligible to receive regulatory milestone payments of up to $525 million and up to $862.5 million on the achievement of certain commercial milestones. Jazz will also be paying Zymeworks tiered royalties between 10% to 20% of the net sales if and when zanidatamab is approved and marketed. Thus, the deal has the potential to reach a total valuation of $1.76 billion.
Developed by Zymeworks, Zanidatamab is an investigational antibody candidate, which has been designed as a treatment option for patients with solid tumors that express HER2. The candidate is being evaluated by ZYME in multiple clinical studies targeting multiple oncology indications.
Apart from zanidatamab, Zymeworks is also developing zanidatamab zovodotin (ZW49) for a range of HER-2 expressing cancers. The candidate is currently undergoing a phase I study to establish its safety and antitumor activity in humans.
Zymeworks entered into a strategic collaboration with BeiGene in 2018, where the latter acquired the exclusive rights to develop and commercialize zanidatamab and zanidatamab zovodotin (ZW49) in Asia (excluding Japan), Australia and New Zealand. In return, ZYME received $40 million as an upfront payment from BeiGene. In addition, Zymeworks will also be entitled to receive development and commercial milestone payments of up to $390 million from BeiGene and potential royalties on future product sales.
Zymeworks Inc. Price
Zymeworks Inc. price | Zymeworks Inc. Quote
Zacks Rank & Stocks to Consider
Zymeworks currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Kamada , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Kamada’s 2022 loss per share have narrowed from 14 cents to 7 cents. During the same period, the earnings estimates per share for 2023 have risen from 26 cents to 42 cents. Shares of Kamada have declined 38.2% in the year-to-date period.
Earnings of Kamada beat estimates in two of the last four quarters and missed the mark twice, witnessing a negative earnings surprise of 62.50%, on average. In the last reported quarter, Kamada’s earnings beat estimates by 433.33%.